Nesina’s Cardiovascular Profile Acceptable: FDA Advisory Panel

Takeda Pharmaceutical said on April 15 that an advisory committee of the FDA has concluded that the company’s dipeptidyl peptidase-4 (DPP-4) inhibitor Nesina (alogliptin) has an acceptable cardiovascular risk profile in patients with type 2 diabetes. The Endocrinologic and Metabolic...read more